Expert Interview
Evaluating the Market Potential of Hua Medicine's HMS5552 in Type II Diabetes Ahead of Mid-Year Phase II Readout. Does the drug have potential to derail the success of major players in the space?
Ticker(s): HUA MEDICINE, ABT, AZN, NVS, NVO, MRK, SNY, GSK, Lupin Pharmaceuticals, RHHBYAn expert with significant experience treating patients with Type II diabetes, who is familiar with the data behind Hua Medicines's drug HMS5552. He or she will also be familiar with the other drugs in the space, and the regulatory process for Type II diabetes drugs.
Can you describe your experience treating patients with Type 2 diabetes? What drugs do you currently use to treat patients, and what other actions are taken in treatment?
Added By: pjloriaCan you discuss the safety and efficacy of existing drugs in the market, particularly Abbott's XIENCE family, AstraZeneca's ONGLYZA, Novartis' Galvus, Eucreas, and Starlix, Novo's Victoza, Lupin's generic Glumetza, Merck's Januvia, Sanofi's Lantus, GSK's Tanzeum, and any other major players I may have missed?
Added By: pjloriaAre there different subsets of patients of Type 2 diabetes patients that need different types of drugs? If so which drugs are best for those subsets?
Added By: pjloriaCan you discuss the most recent Phase Ic/IIa data from Hua on HMS5552? What did it suggest about the safety and efficacy of the drug, and how clinically relevant were the results?
Added By: pjloriaWhat are your expectations for the mid-year Phase II readout on HMS5552? What are important things to look for in the trial?
Added By: pjloriaGiven the current information, how do you view the chances of HMS5552 receiving regulatory approval?
Added By: pjloriaGiven the current information and assuming it gets approved, how do you view HMS5552's role in the Type II diabetes market?
Added By: pjloriaAssuming it gets approved, what percentage of the market do you think HMS5552 could win? Could it be particularly successful in any subset of patients?
Added By: pjloriaAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
